Compared with first-line immunotherapy or chemotherapy alone, combination chemoimmunotherapy for advanced/metastatic non–small cell lung cancer has significantly higher antineoplastic drug and associated medical costs.
John Hartman, PhD
Advertisement
Articles by John Hartman, PhD
Advertisement
Latest Updated Articles
- Better Together? Costs of First-line Chemoimmunotherapy for Advanced Non–Small Cell Lung Cancer
Published: May 18th 2023 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Nerandomilast for Idiopathic Pulmonary Fibrosis
2
Pulling Back Funding for Research COuld Leave HIV Treatment in Worse State: Patrick Sullivan, DVM, PhD
3
Value-Based Care Interventions and Management of CKD Progression
4
HMA Combination Therapy Boosts Survival in Accelerated- or Blast-Phase MPNs
5
